

2010년 순환기관련학회 춘계통합학술대회

# Is Acute Myocardial Infarction in Korea Different From the West? - *KAMIR in Perspective*

Youngkeun Ahn, MD, PhD

The Heart Center of  
Chonnam National University Hospital

# Three Phases of KAMIR Study

**KAMIR-I**  
(Nov 2005-Dec 2006)

**N=8,489**

**KAMIR-II**  
(Jan 2007-Jan 2008)

**N=6,381 (14,870)**

**KORMI**  
(Feb 2008-)

**N=11,656 (26,526)**  
(as of Mar 2010)

# Korea Acute Myocardial Infarction Registry

- ◆ November 2005-January 2008
- ◆ 51 primary PCI centers in Korea
- ◆ **13,133 AMI Pts** with one-year clinical F/U
- ◆  $63 \pm 13$  years of age (9,268 men)

# Baseline Clinical Characteristics: STEMI vs. NSTEMI

	STEMI(n=7,855)	NSTEMI(n=5,278)	p
<b>Age (yrs)</b>	<b>62.0±12.8</b>	<b>64.3±12.3</b>	<b>&lt;0.001</b>
<b>Age group, n (%)</b>			
<55	<u>2,339(29.8)</u>	1,214(23.0)	<b>&lt;0.001</b>
55-64	1,889(24.0)	1,214(23.0)	0.166
65-74	2,200(28.0)	1,692(32.1)	<b>&lt;0.001</b>
≥75	<u>1,427(18.2)</u>	<u>1,158(21.9)</u>	<b>&lt;0.001</b>
<b>Men, n (%)</b>	<u>5,800(73.6)</u>	3,468(65.4)	<b>&lt;0.001</b>
<b>Medical history, n (%)</b>			
Ischemic heart disease	948(12.1)	1,206(22.9)	<b>&lt;0.001</b>
Hypertension	<u>3,577(46.1)</u>	<u>2,855(54.4)</u>	<b>&lt;0.001</b>
Diabetes	<u>1,947(25.2)</u>	<u>1,707(32.6)</u>	<b>&lt;0.001</b>
Hypercholesterolemia	<u>622(9.1)</u>	<u>653(14.1)</u>	<b>&lt;0.001</b>
Current smoking	<u>4,793(61.4)</u>	2,704(51.6)	<b>&lt;0.001</b>
Family history	514(7.4)	335(7.0)	0.443
CVA history	469(5.9)	471(8.9)	<b>&lt;0.001</b>
Heart failure	107(1.4)	213(4.0)	<b>&lt;0.001</b>
Peripheral artery disease	61(0.8)	81(1.5)	<b>&lt;0.001</b>
<b>LVEF (%)</b>	<b>50.3±14.7</b>	<b>53.8±23.6</b>	<b>&lt;0.001</b>


# Coronary Angiographic Findings: STEMI vs. NSTEMI

	STEMI(n=7,290)	NSTEMI(n=4,385)	p
<b>Number of involved vessels, n (%)</b>			
1 vessel disease	3,355(45.7)	1,529(34.9)	<0.001
2 vessel disease	2,188(30.0)	1,363(31.1)	0.224
3 vessel disease	1,592(21.8)	1,305(29.8)	<0.001
Left main (complex)	150(2.1)	167(3.8)	<0.001
Left main (isolated)	25(0.3)	21(0.5)	0.256
<b>Infarct related artery, n (%)</b>			
Left main	115(1.6)	148(3.4)	<0.001
Left anterior descending	3,735(51.2)	1,784(41.0)	<0.001
Left circumflex	706(9.7)	1,218(28.0)	<0.001
Right coronary	2,742(37.6)	1,203(27.6)	<0.001
<b>ACC/AHA lesion classification, n (%)</b>			
Type A	307(4.5)	226(5.6)	0.01
Type B1	1,204(17.7)	752(18.7)	0.185
Type B2	1,809(26.6)	1,179(29.4)	0.002
Type C	3,470(51.1)	1,854(46.2)	0.001
<b>TIMI flow n (%)</b>			
TIMI 0	3,704(53.1)	1,183(28.8)	<0.001
TIMI 1	747(10.7)	537(13.1)	<0.001
TIMI 2	1,030(14.8)	754(18.4)	<0.001
TIMI 3	1,500(21.5)	1,631(39.7)	<0.001


# In-hospital and One-month MACE: STEMI vs. NSTEMI

	STEMI (N= 7,890)		NSTEMI (N= 5,103)		p value
<b>In-hospital death, n (%)</b>	<b><u>504</u></b>	<b><u>(6.4)</u></b>	<b><u>199</u></b>	<b><u>(3.8)</u></b>	<b>&lt;0.001</b>
<b>1-month MACE, n (%)</b>					
Cardiac death	<u>571</u>	<u>(8.5)</u>	<u>255</u>	<u>(5.7)</u>	<b>&lt;0.001</b>
Non-cardiac death	27	(0.4)	19	(0.4)	0.501
Myocardial infarction	30	(0.4)	33	(0.7)	0.821
Re-PCI	62	(1.0)	37	(0.9)	0.324
Target Vessel Revascularization	18	(0.2)	14	(0.2)	0.648
Non-TVR	41	(0.5)	22	(0.4)	0.303
Target Lesion Revascularization	16	(0.2)	10	(0.2)	0.973
CABG	16	(0.2)	20	(0.4)	0.254
<b>Composite</b>	<b><u>705</u></b>	<b><u>(10.4)</u></b>	<b><u>364</u></b>	<b><u>(8.2)</u></b>	<b>0.003</b>

# In-hospital Survival Rate




# One-month Survival Rate



# 12-month MACE: STEMI vs. NSTEMI

	STEMI (N= 5,110)		NSTEMI (N= 3,315)		p value
<b>12-month MACE, n (%)</b>					
<b>Cardiac death</b>	<b>630</b>	<b>(12.3)</b>	<b>315</b>	<b>(9.5)</b>	<b>0.009</b>
Non-cardiac death	67	(1.3)	61	(1.8)	0.681
Myocardial infarction	51	(1.0)	63	(1.9)	0.072
Re-PCI	389	(7.6)	210	(6.3)	0.110
TVR	69	(1.5)	42	(1.4)	0.516
Non-TVR	190	(3.7)	94	(2.8)	0.227
TLR	138	(2.7)	79	(2.3)	0.574
CABG	25	(0.5)	27	(0.8)	0.132
<b>Composite</b>	<b>1,162</b>	<b>(22.7)</b>	<b>676</b>	<b>(20.4)</b>	<b>0.121</b>

# 12-month Survival Rate



# Predictors of Mortality during 12-month Follow-up: All Patients

Variables	95% CI	Hazard ratio	p value
<u>Age</u>	1.061-1.166	1.112	<0.001
≤55			<0.001
≥75			<0.001
<b>Medical history</b>			
MI			0.899
PCI			0.131
Heart failure			0.345
<b>In-hospital complications</b>			
Heart failure			0.566
Shock			0.741
Major bleeding episode			0.741
<u>Ventricular tachycardia &amp; fibrillation</u>	4.380-52.862	15.217	<0.001
<u>LVEF decrease</u>	1.074-1.152	1.112	<0.001
<u>Multi-vessel disease</u>	2.109-7.732	4.038	0.029



# GRACE Study

(Global Registry of Acute Coronary Events)

- ◆ April 1999 - September 2002
- ◆ A total of 24,055 ACS pts
- ◆ 90 hospitals in 14 countries
  - Europe, North & South America, Australia, New Zealand
- ◆ 5,476 STEMI, 5,209 NSTEMI, 6,149 UAP Pts with a median F/U of 6.3 months



# 89 Active Core Study Sites: 17 Clusters in 14 Countries



# Clinical Characteristics: STEMI vs. NSTEMI vs. UAP

	STEMI (n=5,476)	NSTEMI (n=5,209)	UAP (n=6,149)
Age(yrs)*	63.4	<u>68.1</u>	66.6
Men*	<u>72.5%</u>	66.9%	62.5%
<b>Medical history</b>			
Angina pectoris*	46.7%	62.6%	82.8%
DM*	20.6%	<u>26.9%</u>	25.2%
Hypertension*	49.4%	<u>61.2%</u>	65.1%
MI*	19.2%	32.6%	42.0%
PCI*	7.3%	14.0%	24.0%
TIA/stroke*	6.0%	10.0%	8.8%
Heart failure*	5.9%	13.2%	12.8%
CABG*	5.5%	13.9%	20.0%

\*p <0.001

Goldberg RJ, et al. *Am J Cardiol* 2004;93(3):288-93


# In-hospital Outcomes: STEMI vs. NSTEMI vs. UAP

	STEMI (n=5,476)	NSTEMI (n=5,209)	UAP (n=6,149)
<b>Clinical complications</b>			
Cardiogenic shock*	<u>3.1%</u>	1.8%	0.5%
Heart failure*	<u>18.4%</u>	17.9%	9.2%
Major bleeding episode*	4.0%	4.4%	2.1%
Stroke*	1.2%	1.1%	0.4%
<b>Interventional procedures</b>			
Cardiac catheterization*	<u>61.0%</u>	<u>57.6%</u>	44.1%
PCI*	<u>44.4%</u>	<u>30.8%</u>	19.8%
CABG*	5.0%	9.3%	5.2%

# Six-month Outcomes after Hospital Discharge

	STEMI (n=5,476)	NSTEMI (n=5,209)	UAP (n=6,149)	p
<b>End point</b>				
<b>Hospitalization for heart disease</b>	<u>16.2%</u>	<u>19.3%</u>	18.5%	<0.001
<b>Stroke</b>	1.1%	1.5%	0.8%	<0.001
<b>Cardiac catheterization</b>	16.2%	14.7%	15.7%	0.1
<b>PCI</b>	<u>9.3%</u>	<u>8.0%</u>	8.3%	<0.05
<b>CABG</b>	5.0%	7.1%	6.1%	<0.001


# Six-month Survival after Hospital Discharge



# Predictors of Post-discharge Death during Six-month F/U

	STEMI	NSTEMI	UAP
Characteristic	HR (95% CI)	HR (95% CI)	HR (95% CI)
<b>Age (yrs)</b>			
65–74	3.48 (2.00–6.06)	2.17 (1.27–3.72)	3.34 (1.81–6.19)
≥75	8.95 (5.28–15.20)	5.30 (3.19–8.80)	5.29 (2.88–9.72)
<b>Medical history</b>			
<u>Heart failure</u>	2.21 (1.61–3.04)	2.20 (1.71–2.84)	2.23 (1.61–3.08)
<u>MI</u>	1.69 (1.28–2.22)		1.44 (1.09–1.91)
PCI			0.52 (0.35–0.77)
TIA/stroke		1.37 (1.03–1.84)	
<b>Hospital complications</b>			
<u>Cardiogenic shock</u>	1.94 (1.20–3.15)		4.01 (1.73–9.28)
<u>Heart failure</u>	2.16 (1.65–2.83)	1.91 (1.49–2.44)	1.67 (1.17–2.37)
<u>Stroke</u>	2.51 (1.32–4.78)		

# Mortality by Time Interval in Acute Coronary Syndrome



# OPERA Registry

- ◆ October 2002 - September 2003
- ◆ 56 centers in France
- ◆ 2,151 AMI patients with 1-year F/U
- ◆  $64 \pm 14$  years of age (1,588 men)

# Baseline Characteristics: STEMI vs. NSTEMI vs. UAP

	STEMI (n=1476)	NSTEMI (n=610)	P
Age for men, yrs	60±13	65±14	<0.0001
Age for women, yrs	71±14	73±12	0.2
Men (%)	1137 (77.0)	448 (73.4)	0.08
Stable angina	180 (12.2)	129 (21.2)	<0.0001
Unstable angina	149 (10.1)	108 (17.7)	<0.0001
Myocardial infarction	159 (10.8)	136 (22.3)	<0.0001
Heart failure	54 (3.7)	54 (8.9)	<0.0001
PCI	119 (8.1)	78 (12.8)	<0.01
CABG	40 (2.7)	45 (7.4)	<0.0001
Atrial fibrillation	66 (4.5)	55 (9.0)	<0.0001
Stroke	42 (2.9)	37 (6.1)	<0.01
Peripheral arterial disease	88 (6.0)	80 (13.1)	<0.0001
Type II DM	204 (13.8)	120 (19.7)	<0.001
Dyslipidemia	731 (49.5)	306 (50.3)	0.76
Hypertension	649 (44.0)	331 (54.3)	<0.001
Current smoker	583 (39.6)	179 (29.4)	<0.001
Family history	170 (11.6)	62 (10.2)	0.38


# Invasive Procedures during Hospitalization

	STEMI (n=1476)	NSTEMI (n=610)	P
PCI	<u>1047 (71.0)</u>	315 (51.6)	<0.0001
IABP	<u>32 (2.2)</u>	5 (0.8)	<0.05
Pacemaker	43 (2.9)	8 (1.3)	<0.05
Mechanical ventilation	29 (2.0)	10 (1.6)	
CABG	45 (3.1)	30 (4.9)	<0.05

# Clinical Outcomes In-hospital and at One-year

	Total (n=2090)	STEMI (n=1476)	NSTEMI (n=610)
<b>In-hospital outcomes (n=2090)</b>			
<b>Death</b>	<b><u>66 (3.2)</u></b>	<b><u>48 (3.2)</u></b>	<b><u>18 (2.9)</u></b>
<b>Recurrent ischemia and/or QMI</b>	<b>69 (3.3)</b>	<b>50 (3.4)</b>	<b>18 (2.9)</b>
<b>Ischemic stroke</b>	<b>14 (0.7)</b>	<b>11 (0.7)</b>	<b>3 (0.5)</b>
<b>Hemorrhagic stroke</b>	<b>7 (0.3)</b>	<b>6 (0.4)</b>	<b>1 (0.2)</b>
<b>Resuscitated cardiac arrest</b>	<b>32 (1.5)</b>	<b>28 (1.9)</b>	<b>4 (0.7)</b>
<b>One-year outcome (n=1878)</b>			
<b>Death (post-discharge)</b>	<b><u>112 (6.0)</u></b>	<b><u>66 (5.0)</u></b>	<b><u>46 (8.2)</u></b>
<b>Death (cumulative)</b>	<b><u>209 (9.7)</u></b>	<b><u>136 (9.0)</u></b>	<b><u>73(11.6)</u></b>
<b>PCI</b>	<b>222 (12.7)</b>	<b>166 (13.5)</b>	<b>56 (10.9)</b>
<b>CABG</b>	<b>72 (4.1)</b>	<b>38 (3.1)</b>	<b>34 (6.6)</b>

# One-year Survival: STEMI vs. NSTEMI



# Independent Predictors of In-hospital Mortality

Variable

OR (95% CI)

**DL not treated w statin** on adm. (reference: no DL)

3.38 (1.84-6.23)

**Age** (per 10 yr increase)

2.49 (1.90-3.26)

**DM** (reference: no DM)


2.29 (1.30-4.03)

**Low SBP** on admission (per 10 mmHg decrease)

1.29 (1.16-1.45)

**DL treated w statin** on adm. (reference: no DL)

0.04 (0.01-0.28)



# Predictors of One-year Post-Discharge Mortality

	Total population (n=1878)	STEMI (n=1476)	NSTEMI (n=610)
<b>HF</b> (yes vs. no)	2.99 (1.83–4.86)	2.36 (1.17–4.75)	3.88 (1.97–7.67)
<b>Age</b> (per 10 year increase)	2.37 (2.00–2.80)	2.49 (2.02–3.08)	2.20 (1.67–2.91)
<b>DL not treated w statin on adm.</b> (reference: no DL)	2.07 (1.24–3.45)	2.75 (1.49–5.08)	—*
<b>DM</b> (reference: no DM)	1.77 (1.22–2.58)	1.85 (1.15–3.00)	—*
<b>HR</b> (per 10 bpm increase)	1.19 (1.10–1.28)	1.18 (1.07–1.30)	1.23 (1.09–1.39)
<b>SBP</b> (per 10 mmHg decrease)	1.18 (1.11–1.27)	1.17 (1.08–1.28)	1.21 (1.08–1.35)
<b>DL treated with statin</b> (reference: no DL)	0.60 (0.40–0.89)	0.61 (0.37–1.01)	—*

\* A variable with p-value  $\geq 0.05$

# National Heart, Lung, and Blood Institute Dynamic Registry

---

- ◆ 1999-2004
- ◆ Multicenter prospective observational study of consecutive AMI Pts undergoing PCI
- ◆ 903 STEMI, 583 NSTEMI Pts with One-year F/U
- ◆ 62.3 years of age

# Baseline Characteristics: STEMI vs. NSTEMI

	STEMI(n=903)	NSTEMI(n=583)	p
Mean age (yrs)	60.2	<u>62.3</u>	0.001
Age > 65 yrs	34.8%	42.8%	0.002
Women	35.4%	37.7%	0.37
Race/ethnicity			0.18
White	76.6%	71.8%	
Black	14.9%	18.6%	
Asian	2.4%	3.8%	
Hispanic	5.9%	5.7%	
BMI (kg/m <sup>2</sup> )	28.9	28.9	0.69
Previous PCI	11.8%	16.8%	0.001
Previous MI	15.1%	18.7%	0.07
Cerebrovascular disease	5.2%	7.6%	0.06
Renal disease	3.1%	9.5%	<0.001
Peripheral vascular disease	4.2%	8.3%	0.001
Diabetes mellitus	21.6%	<u>27.1%</u>	0.02
Heart failure	4.7%	10.4%	<0.001
Hypertension	56.1%	<u>69.3%</u>	<0.001
Hypercholesterolemia	52.5%	<u>60.4%</u>	0.004
Smoker			0.06
Current	<u>42.6%</u>	36.4%	
Former	27.5%	29.1%	

# Procedural and Angiographic Characteristics

	STEMI(n=903)	NSTEMI(n=583)	p
Ejection fraction (%)	47.4	51.0	<0.001
Vessel number			0.03
1	44.9%	42.4%	
2	34.7%	31.2%	
3	20.5%	26.4%	
Cardiogenic shock	8.6%	2.1%	<0.001
Thrombolytic therapy	37.5%	0.0%	<0.001
Glycoprotein IIb/IIIa inhibitor	58.0%	51.5%	0.013
Lesion location (%)			<0.001
Right	41.0%	31.9%	
Left main	0.2%	0.1%	
Left anterior descending	43.9%	36.3%	
Left circumflex	14.8%	31.7%	
Pre-PCI TIMI 0	33.8%	15.5%	<0.001
Pre-PCI TIMI 2/3	60.8%	80.9%	<0.001
Thrombus	52.3%	26.6%	<0.001
Calcified	20.1%	22.8%	0.16
Ulcerated	23.1%	16.3%	<0.001
Bifurcation	11.5%	12.7%	0.44

# Procedural Results and In-hospital Outcomes

	STEMI	NSTEMI	p
<b>No. of coronary lesions</b>	<b>1,146</b>	<b>799</b>	
Stent use	85.3%	83.2%	0.23
Post-PCI TIMI 2/3	97.1%	98.2%	0.13
Perforation	0.3%	0.1%	0.34
Embolization	2.4%	1.3%	0.08
Side branch occlusion	2.3%	2.6%	0.61
Abrupt closure post-procedure	0.3%	0.3%	0.96
Angiographic success	95.5%	96.7%	0.16
<b>No. of patients</b>	<b>903</b>	<b>583</b>	
MI	1.7%	2.4%	0.31
CABG	1.7%	1.2%	0.47
<b>Ventricular fibrillation</b>	<b><u>9.2%</u></b>	<b><u>3.1%</u></b>	<b>&lt;0.001</b>
Stroke	0.4%	0.2%	0.38
Entry site bleeding requiring transfusion	3.3%	2.1%	0.15
<b>Death</b>	<b><u>4.0%</u></b>	<b><u>1.4%</u></b>	<b>0.004</b>
<b>Mean length of stay (days)*</b>	<b><u>3.9</u></b>	<b><u>2.7</u></b>	<b>&lt;0.001</b>


# Predictors of In-hospital Death after PCI

Factors	OR	95% CI	p
STEMI (vs. NSTEMI)	4.1	1.41–11.78	0.009
Cardiogenic shock	26.7	11.43–62.32	<0.001
Renal disease	18.2	5.94–55.95	<0.001
No previous PCI	9.6	1.11–83.37	0.04
Cancer	3.2	1.12–9.45	0.03
Attempted ostial lesion	3.1	1.05–9.47	0.04
Total occlusion	2.7	1.18–6.25	0.02
Cerebrovascular disease	2.7	0.96–7.47	0.059
Age (yrs)	1.1	1.06–1.15	<0.001
Hypercholesterolemia	0.38	0.16–0.89	0.03

# Cumulative One-year Event Rates by Kaplan-Meier Method

	STEMI (n=903)	NSTEMI (n=583)	p
<b>Death</b>	<b>7.3%</b>	<b>5.5%</b>	<b>0.16</b>
<b>MI</b>	<b>4.5%</b>	<b>5.0%</b>	<b>0.64</b>
<b>CABG</b>	<b>5.1%</b>	<b>2.8%</b>	<b>0.05</b>
<b>Repeat PCI</b>	<b>9.3%</b>	<b>9.2%</b>	<b>0.92</b>
<b>Death/MI</b>	<b>11.3%</b>	<b>10.0%</b>	<b>0.45</b>
<b>Death/MI/Repeat PCI</b>	<b>21.9%</b>	<b>19.2%</b>	<b>0.21</b>

# One-year Mortality: STEMI vs. NSTEMI



# Predictors of One-Year Adverse Events

	Adjusted RR	95% CI	p
<b>Death/MI</b>			
STEMI (vs. NSTEMI)	1.22	0.85–1.76	0.27
Cardiogenic shock	4.43	2.88–6.82	<0.001
Renal disease	3.27	2.05–5.21	<0.001
Peripheral vascular disease	2.03	1.24–3.31	0.005
Congestive heart failure	1.48	0.93–2.38	0.1
Age	1.03	1.02–1.05	<0.001
<b>Repeat revascularization</b>			
STEMI (vs. NSTEMI)	1.06	0.74–1.51	0.75
Multi-vessel disease	2.13	1.33–3.41	0.002
Cardiogenic shock	1.67	0.97–2.87	0.06
Emergency procedure	1.35	0.94–1.95	0.11
Total occlusion	1.32	0.95–1.82	0.1
No. of > 50% lesions	1.21	1.06–1.37	0.004

# **ACTION Registry-GWTG Results: July 1, 2008 – June 30, 2009**

Prepared by:



**Duke Clinical Research Institute**  
DUKE UNIVERSITY MEDICAL CENTER



# Baseline Characteristics: STEMI vs NSTEMI

<b>Variable</b>	<b>STEMI (n=22,025)</b>	<b>NSTEMI (n=32,741)</b>
Mean age $\pm$ SD (yrs)	62 $\pm$ 14	67 $\pm$ 14
Female sex	30%	39%
Diabetes mellitus	23%	35%
Prior MI	20%	29%
Prior CHF	5%	17%
Prior PCI	20%	25%
Prior CABG	7%	19%
Prior Stroke	5%	10%
Prior PAD	5%	12%

# In-hospital Outcome: STEMI vs. NSTEMI

<b>Variable</b>	<b>STEMI (n=22,025)</b>	<b>NSTEMI (n=32,741)</b>
Death*	6.0%	4.0%
Re-infarction	1.1%	0.9%
CHF	6.9%	7.1%
Cardiogenic Shock	6.4%	2.8%
Stroke	0.8%	0.7%
RBC Transfusion**	6.0%	8.5%
Major Bleeding**	12.0%	10.4%

\*Unadjusted mortality


\*\* Among non-CABG pts

# Comparisons Between Major AMI Registries


---

- ◆ **KAMIR**: AMI
- ◆ **GRACE**: ACS
- ◆ **OPERA**: AMI
- ◆ **NHLBID**: AMI undergoing PCI
- ◆ **ACTION Registry-GWTG**: AMI


# Age




# Age Distribution: STEMI vs. NSTEMI



# Gender (Male)




# Smoking




\* p-value not mentioned


# Hypertension



# DM




# Dyslipidemia




\* p-value not mentioned

# In-hospital Mortality



\* p-value not mentioned

# One-Year Mortality





\* p-value not mentioned

# Temporal Trends in ACS Diagnostic Categories

**KAMIR**

**GRACE™**  
GLOBAL REGISTRY OF ACUTE CORONARY EVENTS



# Invasive Reperfusion in Korea vs. Latin America

**KAMIR**

*Nov 2005-Jan 2008*

**GRACE**  
GLOBAL REGISTRY OF ACUTE CORONARY EVENTS


*Apr 1999-Sept 2002*

\*p <0.001


PCI		STEMI (n=8,063)	NSTEMI (n=5,176)	STEMI (n=5,476)	NSTEMI (n=5,209)
Treatment Received		<b>7,197 (89.6%)</b>	<b>3,777 (73%)*</b>	<b>1,248 (44%)</b>	<b>618 (31%)*</b>
Arrival-to-Tx	Mean, min	<b>1,276</b>	<b>3,305*</b>		
	Median, min	<b>190</b>	<b>1,790*</b>	<b>235</b>	<b>3,497*</b>
	0-12 hrs	<b>4,831 (72%)</b>	<b>868 (24.5%)*</b>	<b>643 (62%)</b>	<b>129 (25%)*</b>
	12-24 hrs	<b>518 (7.7%)</b>	<b>618 (17.4%)*</b>	<b>45 (4%)</b>	<b>41 (8%)*</b>
	24-48 hrs	<b>453 (6.8%)</b>	<b>738 (20.8%)*</b>	<b>47 (5%)</b>	<b>60 (12%)*</b>
	>48hrs	<b>906 (13.5%)</b>	<b>1,325 (37.3%)*</b>	<b>308 (30%)</b>	<b>276 (55%)*</b>
GPI (+)		<b>628 (8.7%)</b>	<b>191 (5.1%)*</b>	<b>291 (24%)</b>	<b>178 (29%)*</b>
GPI (-)		<b>6,569 (91.3%)</b>	<b>3,586 (94.9%)*</b>	<b>946 (76%)</b>	<b>437 (71%)*</b>

# Primary PCI Door-to-Balloon Time: Mortality

**KAMIR**





**NRMI-2**



# Primary PCI Distribution of Door-to-Balloon Time

**KAMIR**

**NRMI-2**



**77% visit hospital <3h of symptom onset & No difference in S2FMCT or Tx delay in this group!**

*Park HE, et al. Circ J, In Press*



Cannon CP. Presented at ACC 2000

# STEMI: Door-to-Balloon and Door-to-Needle Times

*KAMIR*

ACTION Registry-GWTG<sup>®</sup>

Patients  
(%)



# STEMI Primary PCI Results: Non-Transfer Patients with DTB $\leq$ 90 min

**KAMIR**


**ACTION Registry-GWTG**



# STEMI Primary PCI Results: DTB Time for Transfer-In Patients

**KAMIR**

**ACTION Registry-GWTG**





# Temporal Trends of STEMI: Reperfusion

KAMIR


ACTION Registry-GWTG

Patients (%)



# Reperfusion Therapy Evolution

## July 1999 / December 2005 – GRACE Registry




# STEMI: Acute Medications

*KAMIR*

ACTION Registry-GWTG<sup>®</sup>

% Use




\* Heparin and GP IIb-IIIa administered any time during hospitalization

# Temporal Trends of STEMI: In-hospital Therapies

KAMIR

GRACE™  
GLOBAL REGISTRY OF ACUTE CORONARY EVENTS




# STEMI: Discharge Medications

*KAMIR*


ACTION Registry- GWTG<sup>®</sup>

% Use




# NSTEMI: Time from Presentation to Procedure

*KAMIR*



ACTION Registry-GWTG<sup>®</sup>




# NSTEMI: Invasive Procedures

*KAMIR*

ACTION Registry-GWTG™



Patients (%)



# NSTEMI: Revascularization Strategy Trends

**KAMIR**

**ACTION Registry-GWTG™**





# NSTEMI: Acute Medications

*KAMIR*

ACTION Registry- GWTG<sup>®</sup>

% Use



\* Heparin and GP IIb-IIIa administered any time during hospitalization



# Temporal Trends NSTEMI: In-hospital Therapies

*KAMIR*

ACTION Registry-GWGTG<sup>®</sup>

% Use


◆ UFH   ■ LMWH   ▲ GP IIb/IIIa inhibitor   ✕ Clopidogrel



# NSTEMI: Discharge Medications

*KAMIR*

ACTION Registry-GWTG™



# Summary and Conclusion

- ◆ **Acute MI in Korea**, compared to the West
  - Similar clinical characteristics, prognoses, and predictors of outcome
- ◆ **NSTEMI**, compared to STEMI
  - Increasing in incidence
  - Worse outcome after discharge
  - Greater attention during F/U to prevent complications
  - Aggressive risk factor modification
- ◆ **STEMI system of care**
  - Transfer protocols, critical pathways, quality improvement program
  - Prospective AMI registry (KAMIR, KorMI)

Celebrating for 100<sup>th</sup> Anniversary of Chonnam National University Hospital

INVITATION

## 2<sup>ND</sup> GWANGJU-BOSTON JOINT CARDIOLOGY SYMPOSIUM

*New Paradigm of Cardiovascular Therapeutics*

**Date :** April 23 (Fri), 2010

**Place :** Myung-Hak Hall, Chonnam National University Medical  
School, Hak-Dong, Gwangju, South Korea

**Course Directors :** Youngkeun Ahn, MD  
Anthony Rosenzweig, MD

**Organized by :** Heart Center, Chonnam National University Hospital  
The Honam Circulation Society of Korea

**Supported by :** National Research Foundation  
Ministry for Health, Welfare and Family Affairs  
Brain Korea 21 Project at CNUMS  
CNUH Research Institute of Clinical Medicine  
University Industry Liaison Office of CNU  
Foundation of Circulation Research

# 경청해 주셔서 감사합니다.